Price History

Hover for the daily close. The dotted line marks the period open.

Compare CYCN with… →

CYCN Key Statistics

As of Sep 4, 2026

Trading

Open: $4.53
Previous Close: $4.96
Day's Range: 4.08–4.53
52-Week Range: 1.03–8.48
Volume: 102.70K
Beta: 1.75

Valuation

Market Cap: $19.90M
P/E Ratio: unprofitable
P/S ratio: 10.47
EPS (ttm): −1.41

Financials (FY)

Revenue (FY): $2.07M+3.70%
Net Income (FY): −$3.53M
Profit margin: 0.00%
Shares Outstanding: 4.68M
1-Year Return: +77.82%

Dividend and dates

Avg Volume: 38.43K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CYCN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−78.24%+12.50%−43.79%−61.86%−74.47%−3.88%−60.56%+234.65%

2019*2020202120222023202420252026*

Year	Return
2026 (partial year)	+234.65%
2025	−60.56%
2024	−3.88%
2023	−74.47%
2022	−61.86%
2021	−43.79%
2020	+12.50%
2019 (partial year)	−78.24%

As of September 4, 2026.

CYCN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$2.07M	−$3.53M	−170.1%
2024	$2.00M	−$3.06M	−152.8%
2023	$0.00	−$5.26M	—
2022	$297.00K	−$44.08M	−14841.1%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$2.07M	—	−$4.97M	−$3.53M	−170.1%
2024	$2.00M	—	−$3.63M	−$3.06M	−152.8%
2023	$0.00	—	−$9.65M	−$5.26M	—
2022	$297.00K	—	−$18.54M	−$44.08M	−14841.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CYCN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	CYCN	Biotechnology median	vs median
P/S ratio	10.47	15.26	31% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

Cyclerion Therapeutics Announces September 4 Record Date For Contingent Value Rights Distribution To Common And Series A Preferred Holders In Connection With Planned Korsana Biosciences Merger
Benzinga2026-08-25

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cyclerion Therapeutics, Inc. (CYCN) carries a market capitalisation of $19.90M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1.

The most recent close on file for CYCN is $4.25, dated September 4, 2026. That is −$0.71 (−14.31%) against the previous close. The 52-week range on file runs from $1.03 to $8.48. The latest close sits 313.83% above that 52-week low.

Financial Health

In fiscal 2025, Cyclerion Therapeutics, Inc. reported revenue of $2.07M. Against the prior fiscal year total of $2.00M, that is a change of +3.70%. The same year closed with a net loss of $3.53M. The reported profit margin is 0%. Trailing earnings per share are −1.41.

Across the 4 fiscal years on file, revenue moves from $297.00K in 2022 to $2.07M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 10.47. On price-to-sales that is 31.4% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +77.82%. Measured over 5 years, that is −41.68% a year compounded. The reported beta is 1.76. Daily returns over the trailing 7 years annualize to a volatility of 206.08%.

Growth & Income

No dividend is on file for CYCN.

Across the complete calendar years on file, 2020 returned +12.50% and 2023 returned −74.47%. Of the 6 complete calendar years on file, 1 finished higher. So far in 2026 the price is +234.65%.

Peer Comparison

Cyclerion Therapeutics, Inc. (CYCN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Cyclerion Therapeutics, Inc.	CYCN	$19.90M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Cyclerion Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Visit website →

Cyclerion Therapeutics, Inc. (CYCN) Stock Analysis